Trial intelligence / Profile preview

Single and multiple rising oral doses of BI 706321 in healthy Japanese and Chinese male subjects

jRCT2071210105Phase 1Suspended

Sponsor
Boehringer Ingelheim
Start
Feb 2022
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 1, randomised, double-blind trial in Crohn's disease comparing BI 706321 with Placebo (2 arms). Primary endpoint: Drug-related adverse events. Started Feb 2022; status: suspended.

02

Drugs

bi 706321
03

Conditions

Crohn's disease

Beyond the preview

Go deeper on jRCT2071210105.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2071210105.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call